Desktop Genetics develops the DESKGEN genome‑editing software platform, providing lab‑validated CRISPR design algorithms that walk users through the full gene‑editing workflow. The platform aggregates the latest advances and expertise so researchers can design reagents, purchase DNA and access external service providers without their own specialist labs. DTG reports the DESKGEN platform has enabled over 2,000 gene‑editing experiments and attracted thousands of users. The company partners with service providers and industry players including Transcriptic, Horizon Discovery, Editas Medicine and enEvolv to offer library design, synthesis and high‑throughput screening services. Recent funding will be used to continue development and commercialization of DESKGEN with a particular focus on integration with next‑generation sequencing pipelines. DTG is also investing the new capital in expanding its sales infrastructure and marketing to drive broader adoption of the technology. Desktop Genetics develops software to support genome-editing workflows, enabling scientists to design, build and test the DNA molecules needed to translate genomic information into medical innovation. Its DESKGEN product allows users to design any genome-editing experiment in any cell line and to generate tailored CRISPR library designs for research. The company raised £1.4m in funding and plans to use the proceeds to continue developing its platform and to expand operations. Leadership named in the article includes Riley Doyla (CEO), Victor Dillard (CFO) and Edward Perello (CBO). The company is based in London, UK.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2015